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A B S T R A C T
Modern day therapy of acute ischemic stroke is based upon intravenous thromboly-
sis, which has altered management of this potentially devastating disease. The urgent 
treatment of acute ischemic stroke must be of the same priority as the treatment of 
acute myocardial infarction. Specific networks must be established to ensure rapid 
transfer of stroke patients to designated hospitals that have the resources in place 
to deliver thrombolysis. Prior to the initiation of any treatment, diseases that mimic 
strokes must be ruled out. Prompt completion of computed tomography (CT) scan-
ning should be performed to rule out hemorrhagic stroke and determination of the 
severity of the stroke using the various grading scales should be made. Recombinant 
tissue-plasminogen activator (rt-PA) is the only thrombolytic agent currently approved 
by the FDA for ischemic stroke treatment. It must be initiated within 3-4.5 hours of 
symptom onset. The extent of the difficulty in establishing the goals outlined above 
is evident from the observed low rate of thrombolysis. Even in the US, the proportion 
of stroke patients being thrombolysed does not exceed 3.5%. This is primarily due to 
patient delayed presentation. However, the goal of initiating thrombolysis as soon as 
possible, to maximize the potential for benefit, should be strongly encouraged.
I N T R O D U C T I O N
Cerebrovascular accidents or strokes continue to represent a serious health prob-
lem with significant associated morbidity and mortality and remain the third leading 
cause of death following cardiac diseases and cancer. In the US, 795,000 new strokes 
are diagnosed annually and result in 150,000 deaths. In patients over 65 years of age, 
25% remain disabled after 6 months resulting in a significant economic burden on 
health resources.1
In accordance with the World Health Organization, stroke is defined as a clini-
cal syndrome characterized by rapid onset of symptoms due to regional neurological 
deficits (at times global) that last more than 24 hours or result in death, with no obvi-
ous cause other than a vascular etiology.2 Stroke can be classified as ischemic (85%) 
or hemorrhagic (15%), with a small percentage (0.5-1%) involving the cerebral veins. 
Ischemic stroke results from either local thrombosis with occlusion of a cerebral ar-
tery, or embolism arising from the heart, aorta or a carotid artery. A total of 20-25 % 
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of ischemic strokes are of cardiac etiology, primarily due to 
atrial fibrillation.
The region of ischemic tissue surrounding the infarction 
core is referred to as the “ischemic penumbra”. This ischemic 
region is dysfunctional but free of permanent damage and with 
reperfusion, function rapidly returns. From primate research 
models, it has been determined that regional neurological 
symptomatology appears when cerebral blood flow falls below 
23 ml/100 gm tissue/min and permanent damage occurs with 
blood flow below 10-12 ml/100 gm tissue/min.3 Therefore, our 
efforts are directed at rapidly reestablishing perfusion of the 
ischemic penumbra.
T H R O M B O L Y S I S
In recent years, thrombolytic therapy has altered manage-
ment of acute ischemic stroke from nihilism to an active inter-
vention. The urgent treatment of acute ischemic stroke must 
be of the same priority as the treatment of acute myocardial 
infarction. The rule, lost time equals lost brain, must predomi-
nate in the thoughts of all who are involved in the transfer, 
receipt and treatment of stroke patients. This is why specific 
networks must be established to ensure rapid transfer of stroke 
patients to designated hospitals that have the ideal resources in 
place, bypassing those that do not.4 In other words, there must 
be specialty centers and stroke units that have established pro-
tocols for rapid diagnosis, admission, and patient treatment. 
Protocol goals include completion of the assessment within 
60 minutes. Modern day therapy of acute ischemic stroke is 
based upon intravenous thrombolysis and intravascular treat-
ments that include intra-arterial thrombolysis, mechanical 
clot removal and angioplasty with stent insertion. The extent 
of the difficulty in establishing the goals outlined above is 
evident from the observed low rate of thrombolysis. Even in 
the U.S., the proportion of stroke patients being thrombolysed 
does not exceed 3.5%. This is primarily due to patient delayed 
presentation. If however, all patients were routed through an 
established emergency network, the percentage would increase 
to 30%. Furthermore, if all patients presented within the first 
hour of symptom onset, more than half would be eligible for 
thrombolytic therapy.4 In specialty stroke units, the percentage 
of thrombolysed patients increased to approximately 10% with 
a significant decrease in mortality up to 50%.
Prior to the initiation of any specific treatment, diseases 
that mimic cerebrovascular accidents such as conversion 
disorder, hypertensive encephalopathy, hypoglycemia, compli-
cated migraine, seizures and tumor, must be ruled out. Such 
disorders account for 13-31 % of presenting cases.5,6 Also, 
completion of computed tomography (CT) scanning should be 
performed to rule out hemorrhagic stroke and determination 
of the severity of the stroke using the various grading scales 
should be made. The time goal for the completion of and 
interpretation of the CT should be no more than 45 minutes.4
Recombinant tissue-plasminogen activator (rt-PA, al-
teplase) is the only thrombolytic agent currently approved by 
the FDA for ischemic stroke treatment. It must be initiated 
within 3 hours of symptom onset and the dose is 0.9 mg/kg to 
a maximum dose of 90 mg; 10 % of the total dose is given ini-
tially over 1 minute and the remainder infused over 60 minutes 
(Tables 1 & 2). Hemorrhagic stroke is the major complication 
of thrombolytic therapy. Risk factors include older age, high 
blood pressure, diabetes, and the severity of the stroke. At this 
time there is insufficient data to justify the use of thrombolytic 
therapy in patients >80 years of age.
The National Institute of Neurological Disorders and 
Stroke (NINDS) rt-PA stroke study established the indication 
for thrombolytic therapy in ischemic cerebrovascular accident. 
Patients who received rt-PA had a 30% higher probability of 
complete or nearly complete neurological recovery at 3 months 
as compared to the patients who received placebo.7 While the 
rt-PA group suffered more symptomatic intracranial bleeds 
(6.4% vs. 0.6%), overall rt-PA resulted in a significant net 
benefit. The benefit observed with thrombolysis persisted at 
1 year.8 Better prognosis was observed in patients with strokes 
of moderate severity, younger age and in those who received 
thrombolytic therapy within 90 minutes. At the same time, 
TABLE 1. Indications and Contraindications of Intravenous 
Thrombolysis in Acute Ischemic Stroke
1. Moderate severity ischemic stroke.
2. Exclusion of hemorrhagic stroke.
3. Initiation within 3 hours of symptom onset.
4. No history of stroke within the last 3 months and no history of 
hemorrhagic stroke.
5. No history of myocardial infarction within the last 3 months.
6. No active bleeding nor history of bleeding within the last 3 
weeks.
7. No anticoagulant use. If on anticoagulant, INR <1.7.
8. Blood pressure <185/110.
9. Platelet count >100,000 mm3.
10. No bleeding or clotting disorder.
11. No brain tumor, structural CNS disease nor history of 
significant head injury within the last 3 months and no history 
of major surgery within the last 2 weeks.
12. No serious systemic disease such as severe renal and hepatic 
dysfunction and terminal cancers.
CNS = central nervous system; INR = international normalized ratio
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other studies with different dosages and longer time win-
dows (up to 6 hours) failed to show a benefit but did show a 
greater number of intracranial bleeds (ECASS-I, ECASS-II, 
Atlantis).9-11
The indications and contraindications for treatment with 
thrombolytics for acute ischemic stroke are the same as those 
identified for the treatment of acute myocardial infarction 
(Table 1).4 It is emphasized that criteria for thrombolysis 
include initiation within the first 3 hours from the time of 
symptom onset, INR must be less than 1.7 in patients taking 
anti-thrombotic medications, and systolic blood pressure must 
be <185 mmHg and diastolic blood pressure <110 mmHg. If 
blood pressure is >185/110 mmHg, anti-hypertensive treat-
ment should be given to achieve permissible blood pressure 
levels (Table 2). If blood pressure targets are not achieved, 
thrombolytics must not be given.
In 2008 the results of ECASS III were published and re-
vealed benefit of thrombolytic therapy when given between 
3 and 4.5 hours after the onset of symptoms.12 Also in 2008, 
a separate study revealed the same benefit for thrombolysis 
given within 3 to 4.5 hours as compared to the results for those 
treated within the first 3 hours.13 In 2009, following the results 
of these two studies and in particular those of ECASS-III, the 
American Stroke Association/American Heart Association 
extended the time limit for thrombolysis to 3-4.5 hours except 
for patient groups excluded from the study: patients >80 years 
of age, patients with severe stroke (NIHSS >25), patients on 
antithrombotics irrespective of INR, and patients with a history 
of cerebrovascular accidents with diabetes.14 However, the goal 
of initiating thrombolysis as soon as possible, to maximize the 
potential for benefit, should not be abandoned. It appears that 
thrombolysis has better results when the occlusion involves 
the middle cerebral artery as compared to the internal carotid 
artery where other therapies must also be considered.15 It is 
probable that the difference in outcome is related to thrombus 
mass which is greater in the internal carotid artery.
The combination of thrombolysis and high frequency 
transcranial-doppler appears to have better results than lone 
thrombolysis.16,17 Intra-arterial thrombolysis requires a spe-
cialized center and is indicated in patients with occlusion of 
the middle cerebral artery <6 hours who are not appropriate 
candidates for intravenous thrombolysis (Class IB), or in those 
who have contraindications to intravenous thrombolysis (e.g. 
recent surgery) (Class IIa C).4 The indications are based upon 
findings of the PROACT II study, in which pro-urokinase given 
to patients with occlusion of the middle cerebral artery <6 
hours after symptom onset revealed significant improvement 
in neurological function at 3 months (40% vs. 25%). However, 
there was an increase in intracranial bleeds (10% vs. 2%).18 
At this time, this treatment is not recommended as a routine 
practice and awaits the results of the SYNTHESIS trial.
Initiation of treatment with heparin and aspirin in the first 
24 hours following thrombolytic therapy is contraindicated 
due to increased risk of intracranial bleeds.4 Aspirin should be 
given to all patients with acute ischemic stroke after the first 
24 hours unless the patient has contraindications. Clopidogrel 
alone or in combination with aspirin is not indicated in the 
treatment of acute ischemic stroke.4
There continue to be multiple unanswered questions re-
lated to thrombolytic treatment in acute ischemic stroke that 
require the completion of large randomized studies. Also, 
considerable efforts need to be made in order to establish 
the networks and specialized treatment centers required for 
handling of stroke patients, as has been accomplished for 
patients with acute myocardial infarction. Just very recently, 
the new thrombolytic agent, tenecteplase (TNK), which is 
currently routinely employed in acute myocardial infarction, 
was also tested in patients with acute ischemic stroke at two 
doses (0.1 and 0.25 mg/kg) and was found to be associated 
with significantly better reperfusion and clinical outcomes 
(particularly the higher dose) than alteplase (rtPA) in patients 
with stroke who were selected on the basis of CT perfusion 
imaging. 19 The higher dose of tenecteplase (0.25 mg/kg) was 
superior to the lower dose of TNK and to alteplase for clinical 
efficacy (in 72% of patients, vs. 40% with alteplase; P=0.02), 
with no significant differences in intracranial bleeding or other 
serious adverse events.
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